-
Jim Daly, EVP and Chief Commercial Officer, to leave Incyte at end
of June, for personal reasons
-
Dr. Barry Flannelly, appointed EVP and General Manager U.S., to
lead regional operating team for United States
-
Incyte to establish Global Product Strategy and BD&L unit to
strategically manage growing portfolio
Incyte Corporation (Nasdaq: INCY) today announced that it has created
two new units to better position the organization for future growth in
the U.S. and internationally. One of these is a U.S. country
organization that will lead commercial and medical affairs in the United
States. In the future, the company expects to establish other similar
country- or regionally-based organizations. The other new unit is a
Global Product Strategy and Business Development & Licensing (BD&L) unit
that will lead global competitive strategies for Incyte’s expanding
portfolio beyond Jakafi® (ruxolitinib), as well as review
business development opportunities.
Jim Daly has indicated he will leave Incyte later this month, and
commented, “My decision to return to California was a personal one. I
leave Incyte knowing that the business is performing well and that the
team is well-prepared to grow Jakafi, and to advance Incyte’s pipeline
of innovative medicines, as the company seeks to make a major difference
for cancer patients in the years ahead.”
Barry Flannelly, Pharm. D., has been appointed to the newly created
position of Executive Vice President and General Manager U.S., effective
immediately. The existing U.S. commercial team, including those
responsible for Jakafi, remains intact and will now report into Dr.
Flannelly. A newly created position of Head of Global Product Strategy
and BD&L is expected to be filled in the near future.
“Jim created significant commercial momentum for Incyte. We sincerely
thank him for all his efforts, including driving towards our goals for
Jakafi, and we wish him well,” stated Hervé Hoppenot, Incyte’s President
and Chief Executive Officer. “Incyte has a large development portfolio
and significant global opportunities, and now is the opportune time for
us to organize the company to include both a regional operating unit for
the U.S. as well as a global strategic product team. We are also
delighted to be able to immediately move Barry into his new role and
draw on his more than 20-year track record in the biopharma industry.”
Barry has been working in oncology since 1987, and began his career in
the pharmaceutical and biotech industry at Rhone-Poulenc Rorer, which
later became Sanofi-Aventis. He has since had roles of increasing
responsibility at Novartis, Abraxis Oncology, Onyx Pharmaceuticals and
Nektar Therapeutics. During his career, he has held positions in medical
affairs, strategic planning, commercial operations, including head of
sales and head of marketing, and business development. He earned his
Doctor of Pharmacy from the University of Maryland School of Pharmacy,
his Master in Business Administration from the University of Baltimore
and his Bachelor of Science in Pharmacy from Massachusetts College of
Pharmacy.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical
company focused on the discovery, development and commercialization of
proprietary therapeutics, primarily for oncology. For additional
information on Incyte, please visit the Company’s website at www.incyte.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150619005092/en/
Copyright Business Wire 2015